Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.

David Reyes-LeivaJoaquín López-ContrerasEsther MogaFrancesc Pla-JuncàElionor Lynton-PonsRicardo Rojas-GarcíaJanina Turon-SansLuis Antonio Querol-Gutiérrez Montse OlivéRodrigo Álvarez-VelascoMarta Caballero-ÁvilaÁlvaro CarbayoAna Vesperinas-CastroPere DomingoIsabel IllaEduard GallardoElena Cortés-Vicente

Published in: Neurology(R) neuroimmunology & neuroinflammation (2022)

This study provides Class IV evidence that patients with MG receiving the mRNA-1273 vaccine did not show clinical worsening after vaccination and that most of the patients achieved high cellular or immune response levels.

Keyphrases

immune response
sars cov
myasthenia gravis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
toll like receptor
patient reported outcomes